155 related articles for article (PubMed ID: 28623682)
21. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
Montazeri AH; Erskine JG; McQuaker IG
Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839
[TBL] [Abstract][Full Text] [Related]
22. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
Bata BM; Pulido JS; Patel SV; Khan SP; Salomao D; Boyce TG; Bothun ED
J AAPOS; 2018 Apr; 22(2):159-161. PubMed ID: 29408337
[TBL] [Abstract][Full Text] [Related]
23. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
24. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-related osteonecrosis of the jaw: model and diagnosis with cone beam computerized tomography.
Barragan-Adjemian C; Lausten L; Ang DB; Johnson M; Katz J; Bonewald LF
Cells Tissues Organs; 2009; 189(1-4):284-8. PubMed ID: 18703870
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
27. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
[TBL] [Abstract][Full Text] [Related]
28. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
[TBL] [Abstract][Full Text] [Related]
29. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
[TBL] [Abstract][Full Text] [Related]
30. Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report.
Ueda K; Ikeda K; Ogawa K; Sukegawa M; Sano T; Kimura S; Suzuki O; Hashimoto Y; Takeishi Y
J Med Case Rep; 2016 Aug; 10(1):236. PubMed ID: 27557810
[TBL] [Abstract][Full Text] [Related]
31. ONJ UPDATE 2018 CONGRESS ABSTRACTS Osteonecrosi delle ossa mascellari (ONJ) da bifosfonati e altri farmaci: prevenzione, diagnosi, farmacovigilanza, trattamento. Alessandria, 5 maggio 2018.
Minerva Stomatol; 2018 Apr; 67(3 Suppl 1):1-45. PubMed ID: 30444325
[No Abstract] [Full Text] [Related]
32. Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: A dreaded complication in a post-liver transplant child.
Jha B; Mohan N; Gajendra S; Sachdev R; Goel S; Sahni T; Raina V; Soin A
Pediatr Transplant; 2015 Nov; 19(7):E177-80. PubMed ID: 26184957
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
34. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
36. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis].
Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355
[TBL] [Abstract][Full Text] [Related]
37. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
38. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
40. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
